Evidence map›Paper›PMID 10583601›Full record

ArticleImmunology1999

Interleukin-12 modulates T-cell responses to microfilariae but fails to abrogate interleukin-5-dependent immunity in a mouse model of onchocerciasis.

P J Hogarth, A E Bianco

Open access · bronzeAbstract read
In one paragraph

Article in Immunology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

P J HogarthDivision of Molecular Biology and Immunology, Liverpool School of Tropical Medicine, UK.
A E Bianco
Liverpool School of Tropical Medicine · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Infection of mice with microfilariae of Onchocerca lienalis induces high levels of protective immunity to reinfection, which is dependent on interleukin (IL)-5 but not IL-4. Here, we have investigated the effect of exogenous IL-12 administration during either the priming or effector phases of the immune response. When administered during priming, IL-12 induced down-regulation of parasite-specific serum immunoglobulin (Ig)E and up-regulation of IgG2a. Antigen-specific IL-4 responses were strongly suppressed, whilst blood eosinophil levels were partially reduced. When administered during a challenge infection, IL-12 did not significantly influence the balance of antibody isotypes, but partially reduced eosinophil production. Antigen-specific IL-4 responses were again completely ablated. Unusually, interferon-gamma (IFN-gamma) responses were not significantly affected following IL-12 administration, either during priming or after challenge infections. Moreover, despite a fall in antigen-specific IL-5 production, the expression of IL-5-dependent immunity, as determined by reduction in worm recoveries, was fully maintained. These data demonstrate that parasite-induced IL-4 can be abrogated without affecting protective immunity to Onchocerca microfilariae in mice. In view of the established role of IL-4 in pathogenesis, this may have important implications for the development of immunoprophylaxis aimed at microfilariae and the alleviation of pathology in onchocerciasis.

Indexed as

AnimalsAntigens, HelminthCells, CulturedEnzyme-Linked Immunosorbent AssayImmunoglobulin EImmunoglobulin GInterferon-gammaInterleukin-12Interleukin-4Interleukin-5MiceMice, Inbred BALB COnchocerciasisSpleenT-LymphocytesAntigens, HelminthImmunoglobulin EImmunoglobulin GInterferon-gammaInterleukin-12Interleukin-4Interleukin-5

Identifiers

PMID10583601
PMCPMC2326952
OpenAlexW2086418439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.